/
PRAX
$339.61-$10.95 (-3.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.1B
28M shares
52-week range
$37.19 – $366.52
92% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$63.31
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $2.4M | $8.6M | $0 |
| Cost of revenue | $1.0K | $679.0K | $0 | $0 | $154.4M | $86.8M | $152.4M | $140.0K |
| Gross profit | −$1.0K | −$679.0K | $0 | $0 | −$154.4M | −$84.3M | −$143.9M | −$140.0K |
| Gross margin | — | — | — | — | — | -3445.8% | -1682.0% | — |
| R&D | $18.8M | $29.6M | $45.0M | $120.3M | $155.0M | $86.8M | $152.4M | $267.1M |
| Operating income | −$22.7M | −$35.8M | −$62.0M | −$167.3M | −$215.0M | −$126.4M | −$200.2M | −$326.2M |
| EBITDA | −$26.3M | −$34.9M | −$61.9M | −$166.9M | −$213.6M | −$122.8M | −$182.5M | −$303.1M |
| Net income | −$26.5M | −$35.5M | −$61.8M | −$167.1M | −$214.0M | −$123.3M | −$182.8M | −$303.3M |
| Net margin | — | — | — | — | — | -5037.9% | -2137.5% | — |
| EPS (diluted) | -306.73 | -348.24 | -103.61 | -58.96 | -69.33 | -18.69 | -10.21 | -13.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-15.17 | $-16.17–$-14.00 | 14 |
| 2027 | $328M | $-10.57 | $-21.61–$-2.46 | 13 |
| 2028 | $1.1B | $7.03 | $-11.84–$30.42 | 16 |
| 2029 | $2.2B | $29.45 | $8.81–$54.97 | 14 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$14.94
Price
$339.61
Implied downside
-96%
Peer comparison
Praxis Precision Medicines, Inc. Common Stock
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
www.praxismedicines.com- Employees
- 10,998
- IPO / List date
- Oct 16, 2020
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds PRAX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 66,230 | $19.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-11-29 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded PRAX yet.
